Genta, Aventis Halt Genasense Expanded Access Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The Aventis-managed program was terminated following an FDA advisory committee’s negative review of the melanoma therapy and withdrawal of the NDA.